scholarly journals The efficacy of a multimodal physical activity intervention with supervised exercises, health coaching and an activity monitor on physical activity levels of patients with chronic, nonspecific low back pain (Physical Activity for Back Pain (PAyBACK) trial): study protocol for a randomised controlled trial

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Crystian B. Oliveira ◽  
Márcia R. Franco ◽  
Chris G. Maher ◽  
Anne Tiedemann ◽  
Fernanda G. Silva ◽  
...  
2009 ◽  
Vol 41 ◽  
pp. 130-131
Author(s):  
José A. Pérez-Turpin ◽  
Juan M. Cortell-Tormo ◽  
Pablo Tercedor-Sánchez ◽  
Alfonso Jiménez ◽  
Juan J. Chinchilla-Mira

2019 ◽  
Vol 6 (1) ◽  
pp. 23
Author(s):  
Hosam Alzahrani ◽  
Martin Mackey ◽  
Emmanuel Stamatakis ◽  
Marina B. Pinheiro ◽  
Debra Shirley

<p> </p><p class="abstract"><strong>Background:</strong> The lifetime prevalence of low back pain (LBP) has been reported to be as high as 84% worldwide. Around 23% of the population has chronic non-specific LBP. Despite the potential health benefits of walking, few studies have investigated its effectiveness in people with non-specific LBP. The primary objective is to examine the efficacy of a Fitbit facilitated walking intervention in people with LBP with medium or high risk of chronicity in reducing disability and pain. The secondary objective is to investigate the efficacy of a Fitbit facilitated walking intervention in increasing physical activity levels in people with LBP.</p><p class="abstract"><strong>Methods:</strong> This prospective, randomised controlled trial<strong> </strong>will involve 68 participants. This study will recruit participants who are aged 18 years or over, have been diagnosed with non-specific LBP with medium or high risk of chronicity and classified as physically inactive. Participants will be randomised into two groups: usual physiotherapy care (n=34) and usual physiotherapy care plus Fitbit facilitated walking intervention program (n=34). The treatment duration will be 8 weeks. Primary outcomes for this study are disability and pain. Secondary outcomes include physical activity level and walking steps, depression, fear of movement and pain catastrophising. The outcomes will be assessed at baseline, post-intervention and 26 weeks post-randomisation follow-up.</p><p class="abstract"><strong>Conclusions:</strong> The results of this study will provide empirical evidence on the efficacy of a Fitbit facilitated walking intervention program, when added to usual care, in a clinical setting for improving disability and pain, and other clinical outcomes in people with LBP.</p><p class="abstract"><strong>Trial Registration: </strong>Australian New Zealand clinical trials registry (Number ACTRN12617001404314).</p>


1994 ◽  
Vol 26 (Supplement) ◽  
pp. S141
Author(s):  
T. Olsen ◽  
S. Dearwater ◽  
A. Kriaka ◽  
J. Cnuley ◽  
R. Anderson ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e031133 ◽  
Author(s):  
Peter Kent ◽  
P O'Sullivan ◽  
Anne Smith ◽  
Terry Haines ◽  
Amity Campbell ◽  
...  

IntroductionLow back pain (LBP) is the leading cause of disability globally and its costs exceed those of cancer and diabetes combined. Recent evidence suggests that individualised cognitive and movement rehabilitation combined with lifestyle advice (cognitive functional therapy (CFT)) may produce larger and more sustained effects than traditional approaches, and movement sensor biofeedback may enhance outcomes. Therefore, this three-arm randomised controlled trial (RCT) aims to compare the clinical effectiveness and economic efficiency of individualised CFT delivered with or without movement sensor biofeedback, with usual care for patients with chronic, disabling LBP.Methods and analysisPragmatic, three-arm, randomised, parallel group, superiority RCT comparing usual care (n=164) with CFT (n=164) and CFT-plus-movement-sensor-biofeedback (n=164). Inclusion criteria include: adults with a current episode of LBP >3 months; sought primary care ≥6 weeks ago for this episode of LBP; average LBP intensity of ≥4 (0–10 scale); at least moderate pain-related interference with work or daily activities. The CFT-only and CFT-plus-movement-sensor-biofeedback participants will receive seven treatment sessions over 12 weeks plus a ‘booster’ session at 26 weeks. All participants will be assessed at baseline, 3, 6, 13, 26, 40 and 52 weeks. The primary outcome is pain-related physical activity limitation (Roland Morris Disability Questionnaire). Linear mixed models will be used to assess the effect of treatment on physical activity limitation across all time points, with the primary comparison being a formal test of adjusted mean differences between groups at 13 weeks. For the economic (cost-utility) analysis, the primary outcome of clinical effect will be quality-adjusted life years measured across the 12-month follow-up using the EuroQol EQ-5D-5L .Ethics and disseminationApproved by Curtin University Human Research Ethics Committee (HRE2018-0062, 6 Feb 2018). Study findings will be disseminated through publication in peer-reviewed journals and conference presentations.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN12618001396213).


Sign in / Sign up

Export Citation Format

Share Document